Multi-Specific Binding Proteins Targeting CD33 and NK Cell Receptors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, including those targeting CD33, often have limited efficacy and are associated with significant adverse side effects, necessitating the development of more potent and specific therapeutic agents.
Innovation Solution
The development of multi-specific binding proteins that bind to CD33 on cancer cells and activate natural killer cells through engagement with the NKG2D and CD16 receptors, enhancing the immune system's ability to target and destroy cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multi-specific binding proteins are used to target CD33 and activate NK cells, then cancer cell lysis potency is improved, but protein structure complexity increases
Solution Approach 1:
The patent combines multiple functional domains into a single binding protein molecule: a CD33-binding domain for tumor targeting, an NKG2D-binding domain for NK cell activation, and a CD16-binding domain for additional NK cell engagement. This merging of multiple specific binding activities into one molecule achieves synergistic cancer cell lysis while simplifying the overall therapeutic approach compared to using separate agents
Solution Approach 2:
The multi-specific binding protein performs multiple functions simultaneously: it targets CD33-positive tumor cells, activates NK cells through NKG2D engagement, and enhances NK cell activation through CD16 engagement. This multi-functionality allows a single agent to accomplish what would otherwise require multiple separate therapies
2Reliability
If multi-specific binding proteins engage multiple NK activating receptors, then NK cell activation is improved, but specificity to target cells may be reduced
Solution Approach 1:
The binding protein is designed with distinct functional domains that have specific local functions: the CD33-binding domain provides tumor cell specificity by targeting only CD33-positive cells, while the NKG2D and CD16 binding domains provide NK cell activation functionality. This spatial separation of functions ensures that NK cell activation occurs primarily at the site of tumor cell contact, reducing off-target effects
Data Source
AI summary
Multi-specific binding proteins that bind to and kill human cancer cells expressing CD33 (Siglec-3) are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of CD33 expressing cancer. The invention relates to multi-specific binding proteins that bind to human cancer cells expressing CD33, and exhibit high potency and maximum lysis of target cells compared to anti-CD33 monoclonal antibodies.